1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shree Ganesh Remedies Ltd.

Shree Ganesh Remedies Ltd.

650.90
INR
-1.75
(-0.27%)
12.02EPS
53.16P/E
8.20BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
15.17
13.64
12.83
16.42
26.5
29.2
48.31
48.71
58.95
74.29
99.18
82.92
84.2
77.04
Basic EPS, GAAP
2.66
1.05
0.9
2.18
4.56
5.16
7.96
9.68
11.08
14.02
22.34
17.96
13.83
12.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
-0.89
-4.31
3.17
3.28
-1.58
-28.47
-0.55
5.81
5.56
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
1.33
0.49
0.5
- -
- -
- -
Book Value per Share
9.64
10.67
11.57
13.64
23.71
27.97
34.81
41.35
50.92
69.23
95.04
113.07
126.95
- -
Tangible Book Value per Share
9.64
10.66
11.56
13.63
23.7
27.91
34.77
40.84
50.53
68.8
94.75
112.7
126.55
- -
Basic Weighted Avg Shares
12
12
12
12
10
12
12
10
12
12
13
13
13
13
Sales/Revenue/Turnover
183
165
155
199
273
353
584
491
713
902
1,248
1,065
1,081
990
Operating Margin (%)
22.3
9.37
8.57
17.81
16.85
22.95
15.6
22.94
21.18
22.52
28.61
28.35
23.21
20.79
Depreciation Expense
5
6
6
5
6
11
23
28
34
38
61
96
105
105
Net Income, GAAP
32
13
11
26
47
62
96
98
134
170
281
231
178
154
Effective Tax Rate (%)
32.41
33.11
33.54
33.14
27.62
28.05
24.48
24.68
25.58
24.64
26.34
26.22
26.05
26.3
Profit Margin (%)
17.52
7.73
6.98
13.29
17.19
17.66
16.47
19.87
18.8
18.87
22.52
21.66
16.43
15.6
Working Capital
73
84
96
122
219
190
251
278
299
406
515
614
642
- -
LT Debt
1
- -
- -
- -
2
2
- -
- -
- -
309
292
296
214
- -
Total Equity
117
129
140
165
287
338
421
500
616
889
1,221
1,452
1,630
- -
Return on Invested Capital (%)
24.38
8.16
6.54
14.89
13.4
16.63
16.19
16.71
18.01
14.84
17.79
12.91
9.8
- -
Return on Capital (%)
28.99
10.61
8.1
17.37
19.96
19.37
24.54
20.66
24.11
18.53
20.29
14.35
10.75
- -
Return on Common Equity (%)
31.98
10.38
8.06
17.31
20.75
19.95
25.35
21.18
24.02
22.62
26.64
17.26
11.53
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
94
- -
LT Borrowings
- -
212
- -
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
5,946
5,392
8,201

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
859
- -
Cash, Cash Equivalents & STI
- -
259
- -
Accounts Receivable, Net
- -
326
- -
Inventories
- -
240
- -
Total Current Liabilities
- -
217
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
94
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
28.9%
27.2%
12.27%
Free Cash Flow
- -
53.13%
-4.35%
Net Income, GAAP
39.85%
17.72%
-23.01%
Sales/Revenue/Turnover
24.12%
19.39%
1.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
248
323
271
244
1,065
2026
247
303
211
332
1,081
2027
144
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3.62
4.97
4.22
5.13
17.96
2026
2.68
3.86
2.41
4.88
13.83
2027
0.87
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chanudubhai Manubhai Kothia
Full Time Employees
224
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Plot No. 6011-12 Ankleshwar GU India 393002
IPO Date
Oct 13, 2017
Website
ganeshremedies.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shree Ganesh Remedies Limited Shree Ganesh Remedies Limited manufactures and exports pharmaceutical drug intermediates, fine and specialty chemicals, and provides contract research and manufacturing services (CRAMS) for pharmaceutical and chemical industries; its core offerings include active pharmaceutical ingredients, veterinary products such as clorsulon, advanced intermediates for oncology, anti-diabetic, and anti-histamine therapies, and over 40 products across human health API intermediaries, veterinary API intermediaries, and specialty chemicals serving life sciences, polymers, agrochemicals, electronics, and aroma sectors. Headquartered in Ankleshwar, Gujarat, India, with manufacturing facilities in the GIDC Estate, the company, founded in 1995, operates globally across more than 15 countries, supplying over 100 customers including Dr. Reddy's, Sun Pharma, Laurus Labs, and European firms, while leveraging expertise in chemical technologies like halogenation, Grignard chemistry, hydrogenation, Suzuki coupling, and chiral synthesis. Recent expansions include the 2022 acquisition of a 20,100 square meter adjoining plot from Jaiswal Pharmachem for Rs 26 crore to boost capacity in pharmaceutical intermediates and specialty chemicals, the commissioning of a GMP-compliant high-pressure reaction block and Block 8 at Dahej in early FY25 for large-scale CRAMS projects, acquisition of 40,554 square meters of land at Dahej for future greenfield developments, and ongoing construction of Block 7 alongside a new pilot facility and R&D lab recognized by the Department of Scientific and Industrial Research in 2021, positioning it to meet rising demand from big pharma and innovator companies.